subih@cdc.gov.tw 1
(1) 3 (2) 4 (3) 6 (4) 7 (5) 7 (6) 11 (7) 11 14 26 35 ( 37 ) 2
10 姙 姙 姙 踪 姙 姙 踪 3
4
5
踪 6
AmpicillinPenicillin, 10 姙 姙 姙 姙 踪 姙 姙 姙 姙 姙 7
姙 姙 姙 姙 姙 姙 姙 姙 姙 姙 姙 姙 姙 姙 姙 姙 姙 姙 8
姙 姙姙 姙 姙 9
姙 姙 姙 姙 踪 姙 Ampicillin Ampicillin Ampicillin 踪 10
姙 姙 踪 恊 11
Fernandez M, Hickman ME, Baker CJ. Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother. 1998;42:1517-9. Harrison LH, Elliott JA, Dwyer DM, Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis. 1998;177:998-1002. Ho MY, Wu CT, Ku YT, Group B Streptococcal infection in neonates: an 11-year review. Acta Paediatr Taiwan. 1999;40:83-6. Jelinkova J, Motlova J. Worldwide distribution of two new serotypes of group B streptococci: type IV and provisional type V. J Clin Microbiol. 1985;21:361-2. 12
Ko WC, Lee HC, Wang LR, Serotyping and antimicrobial susceptibility of group B Streptococcus over an eight-year period in southern Taiwan. Eur J Clin Microbiol Infect Dis. 2001;20:334-9. Lachenauer CS, Kasper DL, Shimada J, Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis. 1999;179:1030-3. Liu JW, Wu JJ, Ko WC, Clinical characteristics and antimicrobial susceptibility of invasive group B streptococcal infections in nonpregnant adults in Taiwan. J Formos Med Assoc. 1997 ;96:628-33. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev. 1998;11:497-513. 39. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ. 1992 ;41:25-32. 13
姙 14
姙 15
姙 16
姙 姙 17
Antimicroblal 姙 姙 Agent R/S+I+R R/S+I+R Clindamycin 130/376(34.6%) 8/18(44.4%) Erythromycin 107/376(28.5%) 5/18(27.8%) Ampicillin 7/376(1.9%) 0/18(0%) Cefepime 12/376(3.2%) 0/18(0%) Vancomycin 0/376(0%) 0/18(0%) Chloramphenicol 32/376(8.5%) 4/18(22.2%) Cefotaxime 3/376(0.8%) 0/18(0%) Ofloxacin 17/376(4.5%) 1/18(5.6%) Penicillin 11/376(2.9%) 0/18(0%) Antimicroblal Agent R/S+I+R R/S+I+R R/S+I+R Clindamycin 34/100(34.0%) 60/155(38.70%) 36/121(29.8%) Erythromycin 27/100(27.0%) 50/155(32.3%) 30/121(24.8%) Ampicillin 1/100(1.0%) 3/155(1.9%) 3/121(2.5%) Cefepime 2/100(2.0%) 6/155(3.9%) 4/121(3.3%) Vancomycin 0/100(0%) 0/155(0%) 0/121(0%) Chloramphenicol 10/100(10.0%) 10/155(6.5%) 12/121(9.9%) Cefotaxime 1/100(1.0%) 1/155(0.7%) 1/121(0.8%) Ofloxacin 4/100(4.0%) 6/155(3.9%) 7/121(5.8%) Penicillin 4/100(4.0%) 6/155(3.9%) 1/121(0.8%) 18
19
20
姙 懐 21
姙 姙 姙 22
B 23
B B 3537 B CDC 24